Activating mutations of ESR1, BRCA1 and CYP19 aromatase genes confer tumor response in breast cancers treated with antiestrogens

Zsuzsanna Suba
  • Recent Patents on Anti-Cancer Drug Discovery, February 2017, Bentham Science Publishers
  • DOI: 10.2174/1574892812666170227110842

Activating mutations affecting ERs have key roles in genome stabilization and tumor response

What is it about?

Activating mutations affecting ERs play key roles in both the machinery of genome stabilization of healthy cells and the restoration of altered genetic pathways of DNA-repair in tumor cells.

Why is it important?

Results of genetic studies on both estrogen- and antiestrogen-treated tumors were reanalyzed and associations among ER-blockade, compensatory restoration of ER-signaling and clinical behavior of cancers were investigated.

Perspectives

professor Zsuzsanna Suba
National Institute of Oncology Budapest

Upregulation of ER-signaling induced by natural estrogens is a beneficial process even in tumor cells promoting their domestication and elimination while in case of antiestrogen administration; increased ER-signaling is a compensatory action to strengthen residual genome stabilization.

Read Publication

http://dx.doi.org/10.2174/1574892812666170227110842

The following have contributed to this page: professor Zsuzsanna Suba